Novel immunotherapies in the treatment of AML: is there hope?
Authors:
- 8 December 2023
- journal article
- research article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2023 (1) , 691-701
Abstract
The success of allogeneic stem cell transplantation has demonstrated the potential for immunotherapy to treat acute myeloid leukemia (AML). Although alternative T-cell-based immunotherapies have shown efficacy, they also pose the risk of on-target off-leukemia hematotoxicity. So far, adoptive autologous or allogeneic chimeric antigen receptor (CAR) T/natural killer cell therapy is almost exclusively employed as a bridge-to-transplant strategy in the context of clinical trials. For now, clinical trials predominantly target lineage-restricted antigens, but emerging approaches focus on leukemia-associated/specific intracellular target antigens, including dual and split targeting strategies. Adapter CAR T cells and T-cell-recruiting bispecific antibodies offer transient exposure with enhanced safety and multitargeting potential against antigen-escape variants. However, these have yet to demonstrate sustained responses and should be used earlier to treat low leukemia burden, preferably if measurable residual disease is present. To address immune dysregulation and enhance T-cell fitness, novel CAR T and bispecific designs, along with combinatorial strategies, might prove essential. Furthermore, genetic associations with inflammatory bone marrow signatures suggest the need for tailored platforms in defined AML subtypes. The eagerly anticipated results of trials investigating magrolimab, an anti-CD47 antibody targeting the “do not eat me” signal in p53-mutated AML, should shed further light on the potential of these evolving immunotherapeutic approaches.Keywords
This publication has 54 references indexed in Scilit:
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyCancer Discovery, 2019
- Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AMLLeukemia, 2018
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid LeukemiaCell, 2018
- Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AMLCancer Cell, 2017
- Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)Journal of Hematology & Oncology, 2017
- Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)Bone Marrow Transplantation, 2017
- Ipilimumab for Patients with Relapse after Allogeneic TransplantationNew England Journal of Medicine, 2016
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agentsLeukemia, 2013
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009